CL2018002196A1 - Combinación de un agente antialérgico con un antagonista muscarínico y/o agonista dopaminérgico para el uso en la prevención/detención de la miopía axial en humanos. - Google Patents

Combinación de un agente antialérgico con un antagonista muscarínico y/o agonista dopaminérgico para el uso en la prevención/detención de la miopía axial en humanos.

Info

Publication number
CL2018002196A1
CL2018002196A1 CL2018002196A CL2018002196A CL2018002196A1 CL 2018002196 A1 CL2018002196 A1 CL 2018002196A1 CL 2018002196 A CL2018002196 A CL 2018002196A CL 2018002196 A CL2018002196 A CL 2018002196A CL 2018002196 A1 CL2018002196 A1 CL 2018002196A1
Authority
CL
Chile
Prior art keywords
prevention
dopamine agonist
arrest
humans
combination
Prior art date
Application number
CL2018002196A
Other languages
English (en)
Inventor
Enzo Maria D'ambrosio
Original Assignee
Dambrosio Enzo Maria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dambrosio Enzo Maria filed Critical Dambrosio Enzo Maria
Publication of CL2018002196A1 publication Critical patent/CL2018002196A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

UNO DE LOS PRINCIPALES PROBLEMAS EN CONTRA DEL USO DE ANTAGONISTAS MUSCARÍNICOS O GOTAS OCULARES AGONISTAS DE DOPAMINA, PARA EL CONTROL DEL CRECIMIENTO OCULAR Y LA PREVENCIÓN DE LA MIOPÍA, ES LA TASA INACEPTABLE DE CONJUNTIVITIS O DERMATITIS IATROGÉNICA. ESTA INVENCIÓN TIENE RELACIÓN CON LA ASOCIACIÓN DE AQUELLOS PRINCIPIOS ACTIVOS CON UN COMPONENTE ANTIALÉRGICO. EN UNA ALTERNATIVA, EL USO OFTÁLMICO DE UNA MOLÉCULA QUE SIMULTÁNEAMENTE TIENE UNA ACCIÓN ANTIMUSCARÍNICA Y/O DOPAMINÉRGICA JUNTO CON UNA FUNCIÓN ANTIHISTAMÍNICA.
CL2018002196A 2016-02-19 2018-08-09 Combinación de un agente antialérgico con un antagonista muscarínico y/o agonista dopaminérgico para el uso en la prevención/detención de la miopía axial en humanos. CL2018002196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2016A000876A ITUB20160876A1 (it) 2016-02-19 2016-02-19 Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Publications (1)

Publication Number Publication Date
CL2018002196A1 true CL2018002196A1 (es) 2019-01-25

Family

ID=55948995

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002196A CL2018002196A1 (es) 2016-02-19 2018-08-09 Combinación de un agente antialérgico con un antagonista muscarínico y/o agonista dopaminérgico para el uso en la prevención/detención de la miopía axial en humanos.

Country Status (13)

Country Link
US (2) US20200253951A1 (es)
EP (1) EP3416617A1 (es)
JP (1) JP2019505542A (es)
KR (1) KR20180117642A (es)
CN (1) CN108883060A (es)
AU (1) AU2017220640B2 (es)
BR (1) BR112018016845A2 (es)
CA (1) CA3013846A1 (es)
CL (1) CL2018002196A1 (es)
IL (1) IL260893B2 (es)
IT (1) ITUB20160876A1 (es)
SG (2) SG10202007417SA (es)
WO (1) WO2017140846A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800005599A1 (it) * 2018-05-22 2019-11-22 Lente a contatto morbida
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
CN114558069A (zh) 2022-04-06 2022-05-31 杭州美依生物科技有限公司 一种眼部舒缓涂抹液及其制备方法
CN115137314B (zh) * 2022-09-02 2022-11-15 首都医科大学附属北京同仁医院 近视风险评估方法、装置及穿戴设备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203666T1 (de) 1989-06-21 2001-08-15 Univ Pennsylvania Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung
CA2567981C (en) 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
EP1853592B1 (en) 2005-01-14 2011-03-02 Schering Corporation Synthesis of himbacine analogs
BRPI0714587A2 (pt) * 2006-07-25 2013-05-07 Osmotica Corp suluÇço oftÁlmica aquosa e uso da nesna
SG151148A1 (en) * 2007-10-05 2009-04-30 Singapore Health Services Pte Method and/or kit for determining response to muscarinic receptor antagonist treatment
ITMO20100369A1 (it) * 2010-12-30 2012-07-01 Enable Innovations Srl Gamma di prodotti per uso oftalmico.

Also Published As

Publication number Publication date
IL260893B1 (en) 2023-04-01
IL260893A (es) 2018-09-20
RU2018133026A (ru) 2020-03-19
CA3013846A1 (en) 2017-08-24
AU2017220640B2 (en) 2022-08-25
SG10202007417SA (en) 2020-09-29
AU2017220640A1 (en) 2018-10-04
EP3416617A1 (en) 2018-12-26
RU2018133026A3 (es) 2020-04-24
KR20180117642A (ko) 2018-10-29
SG11201806599SA (en) 2018-09-27
US20230172904A1 (en) 2023-06-08
IL260893B2 (en) 2023-08-01
WO2017140846A1 (en) 2017-08-24
BR112018016845A2 (pt) 2018-12-26
CN108883060A (zh) 2018-11-23
ITUB20160876A1 (it) 2017-08-19
US20200253951A1 (en) 2020-08-13
JP2019505542A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
CL2018002196A1 (es) Combinación de un agente antialérgico con un antagonista muscarínico y/o agonista dopaminérgico para el uso en la prevención/detención de la miopía axial en humanos.
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
CL2017001718A1 (es) Derivados de glucagón con estabilidad mejorada
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2014000689A1 (es) Composicion para el tratamiento de una condicion ocular que comprende un agonista del receptor de acetilcolina muscarinico m3 y al menos otro agente activo; metodo para tratar presbicia, hipermetropia leve, astigmatismo regular, esotropia acomodativa hipermetropica y glaucoma.
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
CL2015003442A1 (es) Derivados heterociclicos
CL2008001498A1 (es) Uso de un anticuerpo contra el factor d en la prevencion o tratamiento de una condicion ocular asociada al complemento.
CL2019002470A1 (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
CO7250451A2 (es) Formulación oftálmica y método para mitigar la presbicia
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CO6362011A2 (es) Compuesto de anillo fusionado y su uso
CO2017008031A2 (es) Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2016002848A1 (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd
BR112017006113A2 (pt) combinações sinérgicas de auristatina
UY37977A (es) Nuevas combinaciones de desfoliantes
CO2019002245A2 (es) Combinación de agonistas de fxr
CL2021000529A1 (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
CL2012002612A1 (es) Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma.